PATTERSON, N.J., March 04, 2020 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Dr. Christopher von Jako, Chief Executive Officer, will participate in the upcoming investor conferences.
Presenting at the Oppenheimer 30th Annual Healthcare Conference
Date: Tuesday, March 17, 2020
Time: 1:35 pm Eastern Time
Participating in One-on-One Investor Meetings at the BTIG Snowbird Conference
Date: Wednesday, March 18, 2020 and Thursday, March 19, 2020
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders.